Clinicopathologic features of advanced patients with PCA and BRCA1/2 reversion mutations (n = 10) in the absence (n = 3, PARPi‐naïve, patients #1–3) or presence of prior PARPi therapy (n = 7, all olaparib‐treated, patients #4–10). Here, BRCA1 is linked to posterior cortical atrophy.